VERTIGIS
15.11.2022 14:01:36 CET | Business Wire | Press release
VertiGIS, a global market leader and provider of innovative spatial asset management solutions for utilities, telecommunications, government, and infrastructure organizations is entering its next phase of growth and expansion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005035/en/
London-based Andy Berry joins VertiGIS as CEO. (Photo: Business Wire)
VertiGIS is backed by global, technology-focused investment firm Battery Ventures, who saw an opportunity to bring together a distributed ecosystem of leading geographic information systems (GIS) and spatial technology companies under the brand in 2017. VertiGIS has since acquired 10 businesses in North America and Europe and shows no signs of slowing down; in fact, the company intends to grow both organically and through acquisition over the coming years to expand VertiGIS’s offerings into their target industries around the world.
Leading the charge for this new phase of rapid growth is London-based Andy Berry, who was recently appointed as VertiGIS’s CEO. Berry has an extensive background in growing global technology companies with executive roles at ZephyrTel, Pitney Bowes, and LogFire. In his most recent role as Executive Vice President (International, Compass Business Unit) at Infor he was responsible for USD $300 million of revenue across seven independent business units with over 100 products that served 20,000 customers in EMEA and Asia.
“It’s impressive to see how VertiGIS has come together and evolved over the past five years,” said Berry. “This next stage of our growth is all about innovation. While our customers can certainly rely upon us to continue supporting them with our trusted, in-market solutions, they can also expect to see us apply our decades of industry experience and research into cutting-edge technology as we continue to invest in configurable, cloud-ready software that solves their real-world challenges.”
Morad Elhafed, a Battery general partner and VertiGIS board member, noted: “We are thrilled to welcome Andy to the team to further VertiGIS’s mission, which has never been more important given recent geopolitical events impacting governments across Europe, a key VertiGIS customer segment. More broadly, we’re excited to support the company’s organic and inorganic growth strategies across all segments and geographies going forward.”
VertiGIS currently employs over 500 employees in nine countries and serves over 5,000 customers – ranging in size from small businesses and municipalities to global enterprises and major cities – around the world. Their proven, configurable solutions address challenges commonly faced by utilities, telecommunications, government, and infrastructure organizations, with use cases such as:
- Network management (planning, documentation, simulation, analytics);
- Citizen engagement;
- Land management and urban planning;
- Waste management;
- Facilities and asset management (critical infrastructure, large building operations, commercial spaces, manufacturing plants); and
- Transportation (roads, rail, airports, seaports).
VertiGIS solutions are powered by the flexible, purposeful capabilities (e.g., web and mobile viewers, reporting and printing designers, fine-grained security tools, intelligent workflows to digitize processes) found in their VertiGIS Studio™ suite, which can also be licensed separately to help customers extend, enhance, or create their own spatial applications quicker with configuration instead of writing costly custom code.
About VertiGIS:
VertiGIS is a leading spatial asset management and geographic information systems (GIS) solution provider and software developer. Its focus is the development of software solutions and services that help utilities, government, telecommunications, and infrastructure professionals connect their business processes to location technology. The VertiGIS product portfolio is used by over 5,000 customers and millions of end-users around the world and is designed to enhance the capabilities of leading mapping software, most notably Esri’s ArcGIS®. Further information at www.vertigis.com.
About Battery Ventures:
Battery strives to invest in cutting-edge, category-defining businesses in markets including software and services, Web infrastructure, consumer Internet, mobile and industrial technologies. Founded in 1983, the firm backs companies at stages ranging from seed to private equity and invests globally from offices in Boston, the San Francisco Bay Area, London, Israel and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
